Navigation Links
Mechanical heart valves increase pregnancy risk
Date:9/2/2014

Barcelona, Spain Tuesday 2 September 2014: The fact that mechanical heart valves increase risks during and after pregnancy, has been confirmed by data from the ROPAC registry presented for the first time today in an ESC Congress Hot Line session by Professor Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall of the registry's executive committee. The registry found that 1.4% of pregnant women with a mechanical heart valve died and 20% lost their baby during pregnancy.

The Registry Of Pregnancy And Cardiac disease (ROPAC) is an ongoing worldwide registry that includes pregnancies in women with any type of structural cardiovascular disease. It is part of the ESC's EORP programme. Original data are presented today on pregnancy in women with a mechanical valve prosthesis.

Professor Roos-Hesselink said: "Cardiac disease is the leading causes of maternal mortality in both developed and developing countries. Pregnancy induces haemodynamic changes such as an increase of cardiac output, stroke volume and heart rate and demands for an adequate adaptation of the heart. While the normal healthy heart is able to adjust, a structural abnormal heart may be less capable to address these physiological changes, with subsequent increase of maternal and foetal morbidity."

She added: "Pregnancy induces not only a hemodynamic burden but also a hyper-coagulable state. We studied the effect of mechanical prosthetic heart valves on maternal and foetal outcomes. We also examined which anticoagulation regimes were used and what impact they had."

From January 2008 until now, the ROPAC registry has enrolled more than 3 500 pregnant women with structural heart disease, aortic pathology or pulmonary hypertension from 132 centres in 48 countries. Data are presented today on pregnancy in the 212 women with mechanical prosthetic heart valves.

The researchers found that 1.4% of pregnant women with a mechanical heart valve died during pregnancy. Nearly 16% of women had a miscarriage before 24 weeks of pregnancy while 2.8% of women lost the foetus after 24 weeks. Haemorrhagic events occurred in 23% of women and thrombotic events in 6.1%.

Professor Roos-Hesselink said: "Pregnant women with mechanical valve prostheses are at particularly high risk of thrombotic complications, of which thrombosis of the mechanical valve is very serious and occurred in 10 patients (4.7%). They also have a significantly higher mortality (1.4%) during pregnancy compared to the other women with heart disease in the registry (0.2%)."

The researchers found that just 80% of women with a mechanical valve had a live birth. This was significantly lower than the proportion of live births in women in the registry with a tissue valve (98%) or with no prosthetic valve (98%).

A variety of anticoagulation regimes were used during the trimesters of pregnancy (<14 weeks, 14 to 36 weeks, 36 weeks to delivery). The most popular regime, used in 43% of women, was heparin followed by a vitamin K antagonist (VKA), followed by heparin. A further 21% of women were given heparin during all three trimesters, while 20% of women received a VKA during the first two trimesters and heparin in the third (1). The latter regime was associated with significantly higher late foetal mortality (16%) than the other two regimes (approximately 3%).

Professor Roos-Hesselink said: "Effective anticoagulation is essential to prevent thrombotic complications and mortality in pregnant women with mechanical heart valves. However, this inevitably carries an increased risk of haemorrhagic events, particularly during delivery. We found that if vitamin K antagonists are used for anticoagulation in the first trimester there is a significantly increased of late foetal loss. There was no clear difference between the three most common anticoagulation regimes in haemorrhagic and thrombotic complications."

She added: "Pregnancy can be a hazardous situation for women with a mechanical valve prosthesis. Women who need a valve replacement should be told about the pregnancy associated risks, particularly when it is time to choose the type of valve."

Professor Roos-Hesselink concluded: "This study shows a very broad range of anticoagulation regimes used throughout the world. While we found a high rate of pregnancy loss in women using vitamin K antagonists in the entire first trimester, no specific regime turned out to be clearly safest. For (pre-)pregnancy consultation, physicians should be aware that the suggested anticoagulation regimes in current guidelines are based on limited evidence and take individual factors into account when deciding a treatment strategy."


'/>"/>

Contact: ESC Press Office
press@escardio.org
34-670-521-210
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. First gene therapy trial launched for heart patients with mechanical pumps
2. Low-dose anticoagulation therapy can be used safely with new design mechanical heart valve
3. Pradaxa Lawsuit News: Bernstein Liebhard LLP Comments on Study Findings Regarding Use of Pradaxa in Mechanical Heart Valve Patients
4. Study finds mechanical chest compressions are equally as effective as manual CPR
5. NYC’s Living Well Medical Introduces The Gonstead System of Biomechanical Analysis
6. Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk
7. For stroke patients, mechanical clot removal delivers no advantage over standard care
8. Blackall Mechanical, Inc. Expands Project Department to Better Serve Customers in North and South Texas
9. The nanomechanical signature of breast cancer
10. ISHLT issues new guidelines for care of mechanical circulatory support device patients
11. Pradaxa Side Effect Warning: Pradaxa Label to Warn Blood-Thinner Shouldn’t be Used in People with Mechanical Heart Valves, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... 29, 2017 , ... A New York high tech innovator and a Canadian ... effectiveness of Artificial Intelligence (AI) in helping nudge men forward to be more proactive ... President of the Canadian Men’s Health Foundation (CMHF), whose mission is to inspire men ...
(Date:5/28/2017)... ... May 28, 2017 , ... Florida Pain ... announce that Sheldon K. Cho, MD, has joined its Winter Haven practice. ... concentrates on minimally invasive techniques to treat and manage many types of pain. ...
(Date:5/27/2017)... , ... May 27, 2017 , ... From May 21-23, ... Oticon. The three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, ... hearing brand and network of independent hearing healthcare providers to help them stay ahead ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology ... to focus on current legislative activity and the latest regulatory concerns impacting RBMA ... Sunday, Sept. 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. ... “We are thrilled to partner with Cupron® to provide customers with a game ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... -- Global Health Intelligence (GHI), the leading healthcare ... published its 2017 ranking of the Best-Equipped Hospitals in ... analysis from GHI,s hospitals database for Latin America , ... The GHI database covers 86% of the hospitals in ... points for each institution in key areas such as beds, ...
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology: